Annual CFF
$152.85 M
+$151.41 M+10463.37%
December 31, 2024
Summary
- As of March 9, 2025, RAPT annual cash flow from financing activities is $152.85 million, with the most recent change of +$151.41 million (+10463.37%) on December 31, 2024.
- During the last 3 years, RAPT annual CFF has risen by +$11.37 million (+8.04%).
- RAPT annual CFF is now at all-time high.
Performance
RAPT Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$143.12 M
+$143.12 M+100.00%
December 31, 2024
Summary
- As of March 9, 2025, RAPT quarterly cash flow from financing activities is $143.12 million, with the most recent change of +$143.12 million (+100.00%) on December 31, 2024.
- Over the past year, RAPT quarterly CFF has increased by +$134.08 million (+1483.83%).
- RAPT quarterly CFF is now at all-time high.
Performance
RAPT Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$152.85 M
+$142.66 M+1399.28%
December 31, 2024
Summary
- As of March 9, 2025, RAPT TTM cash flow from financing activities is $152.85 million, with the most recent change of +$142.66 million (+1399.28%) on December 31, 2024.
- Over the past year, RAPT TTM CFF has increased by +$142.49 million (+1374.41%).
- RAPT TTM CFF is now at all-time high.
Performance
RAPT TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
RAPT Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10000.0% | +1483.8% | +1374.4% |
| 3 y3 years | +8.0% | +10000.0% | +8.0% |
| 5 y5 years | +206.3% | +311.9% | +206.3% |
RAPT Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | >+9999.0% | at high | -100.0% | at high | >+9999.0% |
| 5 y | 5-year | at high | >+9999.0% | at high | -100.0% | at high | >+9999.0% |
| alltime | all time | at high | >+9999.0% | at high | -100.0% | at high | >+9999.0% |
RAPT Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $152.85 M(>+9900.0%) | $143.12 M(>+9900.0%) | $152.85 M(+1399.3%) |
| Sep 2024 | - | $0.00(-100.0%) | $10.20 M(-1.0%) |
| Jun 2024 | - | $701.00 K(-92.2%) | $10.30 M(-0.6%) |
| Mar 2024 | - | $9.04 M(+1872.9%) | $10.37 M(+616.4%) |
| Dec 2023 | $1.45 M(-98.9%) | $458.00 K(+332.1%) | $1.45 M(-98.1%) |
| Sep 2023 | - | $106.00 K(-86.2%) | $76.35 M(-6.3%) |
| Jun 2023 | - | $767.00 K(+561.2%) | $81.49 M(-37.9%) |
| Mar 2023 | - | $116.00 K(-99.8%) | $131.16 M(-0.0%) |
| Dec 2022 | $131.18 M(-7.3%) | $75.36 M(+1335.1%) | $131.18 M(+132.5%) |
| Sep 2022 | - | $5.25 M(-89.6%) | $56.42 M(+9.3%) |
| Jun 2022 | - | $50.44 M(>+9900.0%) | $51.64 M(-63.2%) |
| Mar 2022 | - | $132.00 K(-78.0%) | $140.31 M(-0.8%) |
| Dec 2021 | $141.48 M | $601.00 K(+27.3%) | $141.48 M(-2.7%) |
| Sep 2021 | - | $472.00 K(-99.7%) | $145.44 M(+0.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | $139.11 M(>+9900.0%) | $145.13 M(+2006.4%) |
| Mar 2021 | - | $1.30 M(-71.5%) | $6.89 M(-90.9%) |
| Dec 2020 | $75.46 M(+51.2%) | $4.56 M(+2663.6%) | $75.46 M(-28.6%) |
| Sep 2020 | - | $165.00 K(-80.9%) | $105.64 M(-0.5%) |
| Jun 2020 | - | $864.00 K(-98.8%) | $106.14 M(-5.9%) |
| Mar 2020 | - | $69.87 M(+101.1%) | $112.76 M(+126.0%) |
| Dec 2019 | $49.90 M(-5.4%) | $34.74 M(+5140.0%) | $49.90 M(+32.1%) |
| Sep 2019 | - | $663.00 K(-91.1%) | $37.78 M(+1.6%) |
| Jun 2019 | - | $7.49 M(+6.7%) | $37.18 M(-37.7%) |
| Mar 2019 | - | $7.01 M(-69.0%) | $59.66 M(+13.1%) |
| Dec 2018 | $52.73 M(+75.2%) | $22.62 M(>+9900.0%) | $52.73 M(+75.1%) |
| Sep 2018 | - | $62.00 K(-99.8%) | $30.11 M(+0.2%) |
| Jun 2018 | - | $29.96 M(>+9900.0%) | $30.05 M(>+9900.0%) |
| Mar 2018 | - | $87.00 K | $87.00 K |
| Dec 2017 | $30.10 M | - | - |
FAQ
- What is RAPT Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for RAPT Therapeutics?
- What is RAPT Therapeutics annual CFF year-on-year change?
- What is RAPT Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for RAPT Therapeutics?
- What is RAPT Therapeutics quarterly CFF year-on-year change?
- What is RAPT Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for RAPT Therapeutics?
- What is RAPT Therapeutics TTM CFF year-on-year change?
What is RAPT Therapeutics annual cash flow from financing activities?
The current annual CFF of RAPT is $152.85 M
What is the all time high annual CFF for RAPT Therapeutics?
RAPT Therapeutics all-time high annual cash flow from financing activities is $152.85 M
What is RAPT Therapeutics annual CFF year-on-year change?
Over the past year, RAPT annual cash flow from financing activities has changed by +$151.41 M (+10463.37%)
What is RAPT Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of RAPT is $143.12 M
What is the all time high quarterly CFF for RAPT Therapeutics?
RAPT Therapeutics all-time high quarterly cash flow from financing activities is $143.12 M
What is RAPT Therapeutics quarterly CFF year-on-year change?
Over the past year, RAPT quarterly cash flow from financing activities has changed by +$134.08 M (+1483.83%)
What is RAPT Therapeutics TTM cash flow from financing activities?
The current TTM CFF of RAPT is $152.85 M
What is the all time high TTM CFF for RAPT Therapeutics?
RAPT Therapeutics all-time high TTM cash flow from financing activities is $152.85 M
What is RAPT Therapeutics TTM CFF year-on-year change?
Over the past year, RAPT TTM cash flow from financing activities has changed by +$142.49 M (+1374.41%)